# HalioDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haliodx

- Industry: Healthcare
- Headquarters: Marseille, France
- Website: www.haliodx.com
- Total disclosed funding: $12M
- Latest round: Series B (Feb 2, 2018)
- Investors on record: 7

## About

HalioDx SAS is a Marseille-based company specializing in advanced genomic and biomarker analysis services, providing innovative solutions for precision medicine and diagnostic testing in healthcare and life sciences.HalioDx SAS, founded in 2015 in Marseille, France, focuses on genomic analysis for precision medicine. The company has undergone several strategic developments, including its most recent funding round, which involved a Series B investment, raising EUR 9.249 mn. The firm has completed a total of 3 deals to date. Jerome Galon, the founder, has a notable background in genomics and previously contributed to advancements in cancer diagnostics and treatments. The firm was recently acquired by Veracyte, Inc. on June 1, 2021, in a deal worth approximately EUR 260 mn.HalioDx specializes in providing advanced genomic and biomarker analysis services that cater to a diverse range of clients in the healthcare and life sciences sectors. Their core offerings include innovative solutions for precision medicine, diagnostic testing, and drug discovery, leveraging technology to deliver reliable insights. The company focuses on addressing challenges in personalized healthcare, enabling providers to utilize genomic data to improve patient outcomes. HalioDx serves hospitals, clinical laboratories, and pharmaceutical companies in North America and Europe, where demand for these analytical services is growing.In 2016, HalioDx reported a revenue of EUR 10,932,454.40 with an EBITDA of EUR -2,010,057.40. The company generates revenue through a fee-for-service model, offering genomic analysis and testing services to various clients, supported by tailored pricing plans that include comprehensive packages and subscription-based models for ongoing services.HalioDx plans to expand its product offerings and enter new markets. The company is focusing on developing new diagnostic tools and solutions aimed at enhancing precision medicine capabilities. With the recent funding of EUR 9.249 mn, HalioDx intends to invest in research and development, targeting expansion in North America and Europe by 2023 to meet the increasing demand for advanced diagnostic services. The acquisition by Veracyte, Inc. will also facilitate HalioDx’s growth trajectory, enabling access to a broader range of resources and networks in the healthcare sector.

## Funding rounds

- Series B, Feb 2, 2018, $12M — Capricorn Partners, Turenne Groupe, Amundi Private Equity Funds, Sofipaca, Bpifrance Investissement, MI Care, BNP Paribas Developpement

## Investors

- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series B
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B
- Amundi Private Equity Funds — Series B
- Sofipaca (https://capitalatlas.ai/funds/sofipaca) — Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series B
- MI Care — Series B
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series B